Renal Cell Carcinoma - Pipeline Review, H2 2015

Renal Cell Carcinoma - Pipeline Review, H2 2015

Code: GMDHC7422IDB | Published: Dec-2015 | Pages: 727 | Global Markets Direct
Price :
$2,000.00
USD

* Required Fields

$2,000.00

Details

Renal Cell Carcinoma - Pipeline Review, H2 2015

Summary

Global Markets Directs, Renal Cell Carcinoma - Pipeline Review, H2 2015, provides an overview of the Renal Cell Carcinomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note
AbbVie Inc.
Acceleron Pharma, Inc.
Advenchen Laboratories, LLC
Altor BioScience Corporation
Ambrx, Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
arGEN-X BV
Argos Therapeutics, Inc.
Arrowhead Research Corporation
Astellas Pharma Inc.
Bayer AG
Beta Pharma, Inc.
Bio-Cancer Treatment International Limited
Bionomics Limited
Bionovis SA
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Calithera Biosciences, Inc.
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cerulean Pharma, Inc.
Chipscreen Biosciences Ltd
Cytune Pharma SAS
Dr. Reddys Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genor BioPharma Co., Ltd.
GenSpera, Inc.
GlaxoSmithKline Plc
Hetero Drugs Limited
Horizon Pharma Plc
Hospira, Inc.
Hutchison MediPharma Limited
immatics biotechnologies GmbH
Immune Design Corp.
Immunicum AB
ImmunoGen, Inc.
Inbiopro Solutions Pvt. Ltd.
InteRNA Technologies B.V.
KAHR medical Ltd.
Karyopharm Therapeutics, Inc.
KineMed, Inc.
Kyowa Hakko Kirin Co., Ltd.
Mabion SA
MacroGenics, Inc.
MediaPharma s.r.l.
MediGene AG
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mologen AG
Monopar Therapeutics LLC
Mycenax Biotech Inc.
Nektar Therapeutics
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncobiologics, Inc.
OncoMax
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
Panacea Biotec Limited
Panacela Labs, Inc.
Peloton Therapeutics, Inc.
Pfizer Inc.
PharmaEssentia Corporation
Pono Pharma
Prima BioMed Ltd.
PsiOxus Therapeutics Limited
Rexahn Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Sevion Therapeutics, Inc.
Sorrento Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syndax Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
TC BioPharm Limited
Theravectys SA
Threshold Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc.
TVAX Biomedical, Inc.
Tyrogenex, Inc.
Vascular Biogenics Ltd.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct